Pharmaceuticals News

U.S. commercial launch of VARUBI® (oral rolapitant) well underwayNiraparib Phase 3 NOVA results expected in Q2 2016 are positioned to be the first data from a randomized, prospective Phase 3 trial...

2015 Global Net Revenue for PROCYSBI® of $94.2 Million Reported 2016 Global Net Revenue Guidance of $115 to $125 Million 2016 Anticipated PROCYSBI Growth of 25%-30% Year-Over Year Company to Host...

MENLO PARK, Calif., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the fourth quarter and year ended December 31, 2015 and recent events. ...

-- Company Preparing to Initiate Phase 3 Program in 2016 -- -- Naloxone PRT Uniquely Targets the Cause of OIC in the Gastrointestinal Tract; Minimizes Undesirable Systemic Adverse Effects -- ...

TUSTIN, Calif., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the...

NEW YORK, Feb. 25, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress...

WALTHAM, Mass., Feb. 25, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has entered into definitive agreements with...

Full year 2016 revenues projected to be $130.0 to $140.0 millionTop-line data from sparsentan Phase 2 DUET study expected 3Q16Clinical trial evaluating efficacy of RE-024 in PKAN to initiate in...

Limited number of asymptomatic, transient rises in serum sodium triggers pre-specified safety review and protocol clinical holdNo CR845-associated serious adverse events (SAEs) observed to date ...

SAN DIEGO, Feb. 25, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and...